Collaborative Innovation through the CTSA Program

The NCATS CTSA Program collaborative innovation suite of awards support team-based research to develop, demonstrate and disseminate innovations that can improve the translational science process to turn laboratory, clinic and community observations into interventions and benefit public health. The suite of opportunities aims to provide support to investigators to tackle a translational science problem no one hub can solve alone or to disseminate a validated solution developed at one hub to other hubs. These collaborations test innovations in different hub settings and adapt such innovations for further dissemination within and outside the CTSA Program consortium, if appropriate. In developing the collaborative innovation funding opportunity announcements (FOAs), NCATS carefully considered input from the National Academy of Medicine (formerly the Institute of Medicine) and a report from a working group (PDF - 414KB) of the NCATS Advisory Council. The funded projects reflect the CTSA Program goals and cover a broad spectrum of translational science.

A graphic representation of the types of NCATS CTSA Program Collaborative Innovation awards and the eligibility, review type, and purpose for each.

Funding

Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)

  • This type of opportunity will support investigators from two or more CTSA Program hub institutions to either: 1) form new collaborations, or to 2) significantly expand the scientific scope of existing collaborations, or to 3) engage new collaborators in pre-existing collaborations to solve a translational science problem no one hub can solve alone, or disseminate a solution to a translational science problem developed at one hub to other hubs, thereby testing its robustness to different hub environments and structures and adapting it for further dissemination within and outside the CTSA Program consortium if appropriate. 

Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)

  • This type of opportunity will support investigators from three or more CTSA Program hub institutions (see below under Eligible Individuals) to either: 1) form new collaborations, or to 2) significantly expand the scientific scope of existing collaborations, or to 3) engage new collaborators in pre-existing collaborations to solve a translational science problem no one hub can solve alone, or disseminate a solution to a translational science problem developed at one hub to other hubs, thereby testing its robustness to different hub environments and structures and adapting it for further dissemination within and outside the CTSA Program consortium if appropriate.

Limited Competition: Administrative Supplements to Enhance Network Capacity: Collaborative Opportunities for the CTSA Program (Admin Supp)

  • This type of opportunity is intended to enhance network capacity through implementing, assessing, and/or disseminating discoveries in methods, approaches, education and training in clinical and translational science. Funds will allow investigators from two or more different CTSA Program hubs to form collaborations within the CTSA Program network and/or with external partners to implement, assess and/or disseminate discoveries across the network. These activities must be within the scope of the approved aims of the parent award and provide significant advances across the translational science spectrum.

Funded Collaborative Suite of Awards

CTSA Program Collaborative Innovation Awards (CCIA)

The funded projects reflect the CTSA Program goals and cover a broad spectrum of translational science, ranging from diagnostics and clinical trial design to patient-reported outcomes and community engagement.

Administrative Supplements 

The funded supplements reflect the CTSA Program goals and disseminate local innovations ranging from informatics, training and education of the translational science workforce, methods and processes, community engagement strategies, entrepreneurship, team science, clinical trial management and recruitment, regulatory guidance, to approaches to precision medicine.